Liquidia (LQDA) Profit After Tax Growth (3y) (2023 - 2026)
Liquidia (LQDA) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Liquidia | 6.39 Bn | 6.11 Bn | 160.92 Mn | 73.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.00% |
| Mar 31, 2026 | 86.63% |
| Dec 31, 2025 | 61.74% |
| Sep 30, 2025 | 27.03% |
| Jun 30, 2025 | -63.88% |
| Mar 31, 2025 | -34.01% |
| Dec 31, 2024 | -49.35% |
| Sep 30, 2024 | -62.13% |
| Jun 30, 2024 | -63.56% |
| Mar 31, 2024 | -48.52% |
| Dec 31, 2023 | -19.50% |
| Sep 30, 2023 | -1.80% |
| Jun 30, 2023 | -19.11% |
| Mar 31, 2023 | 7.40% |